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1. Introduction 
Today, the relationship between inflammation and cancer has been widely accepted. 
Cancer-related inflammation (CRI) was even considered as ‘the other half of the tumor’. 
Angiogenesis plays an important role in the evolution of both cancer and inflammatory 
diseases. It has been well established that inflammation is a defensive reaction of living 
tissue to injury which involves vascular response. The establishment of tumor also generates 
new blood vessel formation, mainly through hypoxia. In addition, the inflammatory cells 
infiltrating the tumor tissue, particularly tumor-associated macrophages (TAM), also 
contribute to tumor angiogenesis. Angiogenesis triggered by CRI has been considered as a 
potential target for cancer therapy.  
As depicted in Fig. 1, the multistep development of cancer is thought to require six 
biological capabilities including: sustaining proliferative signaling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, 
and activating invasion and metastasis [2]. Recently, cancer-related inflammation, a key 
component of tumor microenvironment, has been proposed to promote tumor progression 
and serve as the seventh hallmark of tumor (Fig. 1) [1].  
Cancer inflammation has long been proposed as promoter of tumor growth. As early as in 
the 19th century, observations have been made that tumors often arose at sites of chronic 
inflammation, and that inflammatory cells were present in human tumors [3]. Although this 
idea has waned for a long time, a renaissance of the inflammation-cancer connection 
suggested by multiple lines of evidence has led to a currently accepted paradigm [3-5]. 
These lines of evidence categorized by Mantovani et al. [5] are listed below.  
 Inflammatory diseases (e.g., inflammatory bowel disease) could increase the risk of 
developing different types of cancer including bladder, cervical, gastric, intestinal, 
esophageal, ovarian, prostate and thyroid tumors. Inflammatory cells, chemokines and 
cytokines are present in the microenvironment of all tumors in both experimental animal 
models and humans from the earliest stages of development. Signs of ‘smoldering’ 
inflammation are present even in tumors for which a firm causal relationship to infection 
has not been established (for example, breast tumors). Epidemiological studies have 
revealed that chronic inflammation predisposes to different types of cancer suggesting 







Fig. 1. Hallmarks of cancer [1].  
 Signaling pathways involved in inflammation operate downstream of oncogenic 
mutations (such as mutations in the genes encoding RAS, MYC and RET). 
 Adoptive transfer of inflammatory cells or overexpression of inflammatory cytokines 
promotes the development of tumors. 
 Non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of incidence of several 
tumors (e.g., colon and breast cancer) and mortality caused by these cancers. Protection 
offered by NSAIDs supports the idea that inflammation is a risk factor for certain 
cancers. 
 The targeting of inflammatory mediators (e.g., TNF-ǂ and IL-1ǃ), key transcription 
factors involved in inflammation (e.g., NF-κB and STAT3) and tumor infiltration of 
inflammatory cells decreases the incidence and spread of various tumors. 
2. Key factors and cells in cancer-related inflammation 
In the tumor microenvironment, products of inflammatory cells influence almost every 
aspect of tumorigenesis and tumor progression [5]. Their effects on tumor angiogenesis will 
be discussed in more details in Part 3.  
Two pathways have been schematically identified as the connection between initiation of 
cancer and inflammation, as intrinsic pathway and extrinsic pathway. In the intrinsic 
pathway, internal genetic events which cause neoplasia, at the same time, would trigger the 
expression of inflammation-related programs and then guide the construction of an  
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Factors  Biological activity 
IL-1ǃ Elevated level in patient with leukoplakia and oral cancer [71]; Inducing 
chemical carcigenesis of fibrosarcomas, in vivo [72]; host derived or exogenous 
IL-1ǃ enhancing tumor invasiveness and metastasis, in vitro and in vivo [73] 
IL-6 Involved in tumor progression, such as in multiple myeloma, plasmacytomas, 
intestinal cancer, in vitro and in vivo, mainly through NF-κB and STAT3 [74]; 
Elevated IL-6 level be correlated with HCC, in vivo experiment and in clinical 
[75, 76]; Elevated level in patient with leukoplakia and oral cancer [71] 
IL-23 Elevated in intestinal polyps and colorectal carcinoma [77] 
IFN-Ǆ Enhancing the antitumor activity of alveolar macrophages, in vitro [78] 
TNF-ǂ Elevated level in patient with leukoplakia and oral cancer [71] 
LXs Inhibiting the tumor growth of transplanted H22 in mice, in vitro and in vivo 
[79]; inhibiting hepatocyte growth factor-induced invasion of human hepatoma 
cells, in vitro [80] 
Table 1. Effect of variety of inflammatory mediators on tumor progression. 
inflammatory microenvironment inside tumor tissue. RET oncogene in papillary carcinoma 
of the thyroid is a typical example for this intrinsic pathway [6]. It should be noticed that 
although those oncogenes might be representative of different pro-inflammatory molecular 
classes and actions, they will share the capacity to orchestrate all CRI circuits [1].  
As in the extrinsic pathway, inflammatory conditions would just help to facilitate tumor 
development. Chronic inflammation acts as a trigger to increase cancer risk or progression. 
Chronic inflammatory conditions associated with cancer development include chronic 
infections (e.g., Helicobacter pylori for gastric cancer and mucosal lymphoma; papilloma 
virus and hepatitis viruses for cervical and liver carcinoma, respectively), autoimmune 
diseases (e.g., inflammatory bowel disease for colon cancer) and inflammatory conditions of 
uncertain origin (e.g. prostatitis for prostate cancer) [2].  
There is also close connection between inflammation and metastasis. A successful 
establishment of a metastatic lesion depends on both intrinsic properties of the tumor cells 
and factors derived from the tumor microenvironment that often contains secretory 
products of immune cells such as IL-1, IL-6, TNF and RANKL. All of these are known to 
augment tumor cells’ ability to metastasize by affecting several steps in the cells’ 
dissemination and implantation at secondary sites [7].  
Notably, vascular endothelial growth factor-A (VEGF-A), one of the most important 
stimulators in tumor angiogenesis, is also an inflammatory factor inducing strong 
macrophages chemotaxis in tumor [8].  
Besides the cytokines and chemokines mentioned above, in recent years, short noncoding 
RNAs termed microRNAs (miRNAs) have been described as a novel class of molecular 
promoters of neoplastic progression that control gene expression on the post-transcriptional 
level [9]. Some of the miRNAs play a crucial role both in inflammation and cancer. For 
example, miR-21 has been found to be deregulated in most types of cancers and therefore 
was classified as an onco-miR. Meanwhile, miR-21 also plays roles in chronic inflammatory 
diseases including cardiac and pulmonary fibrosis as well as myocardial infarction [10]. In 
contrast, miR-146a acts as a molecular brake on inflammation, myeloid cell proliferation, as 






3. Introduction about tumor angiogenesis  
Although induction of new blood vessels by solid tumors had been first recognized by 
Virchow nearly 150 years ago [12], tumor angiogenesis is frequently linked to the name of 
Dr. Judah Folkman who founded this field nearly 40 years ago. Folkman proposed that the 
growth of all solid tumors is dependent on angiogenesis and suggested that suppression of 
tumor blood vessel growth would offer a new option for cancer therapy [13] . 
Angiogenesis, the sprouting of new blood vessels from pre-existing endothelium, is an 
important component of various biological processes including embryonic vascular 
development, organ regeneration, wound healing, and recovery from myocardial ischemia 
or peptic ulcer. However, it is also a part of many pathologies that depend on 
neovascularization, such as diabetic retinopathy, rheumatoid arthritis and tumor growth 
[14]. The expansion of cancer requires the formation of new blood vessels due to oxygen and 
nutrients that can obtained by diffusion. Notably, the newly formed tumor vessels also 
provide a gateway for tumor cells to enter circulation and metastasize to distant organs [15].  
Tumor vessels are characterized by lack of maturation, absence of smooth muscle cells, 
missing adrenergic innervation and lymphatic drainage, discontinuous endothelial lining, 
and sinusoidal vessel plexuses [16]. Tumor vasculature differs in many aspects from the 
vasculature of normal organs. The vessel diameter varies significantly in most tumors as 
compared with vessels in normal tissues. It is still unclear whether the vascular architecture 
of an individual tumor is tumor type-specific. 
Our knowledge of the mechanisms underlying angiogenesis has increased dramatically in 
the past decades. Angiogenesis is a complex multistep process involving close orchestration 
of endothelial cells, soluble factors, and extracellular matrix. Usually, the vascular 
endothelium is a quiescent tissue with a very low turnover rate. However, in response to 
angiogenic factors, endothelial cells emerge from quiescence and become motile and 
proliferative. The initiation or termination of angiogenesis is tightly controlled by the net 
balance between positive and negative regulators. Positive factors include EC mitogenic 
factors such as fibroblast growth factor-1 and -2 (FGF-1, -2), transforming growth factor-α 
(TGF-α), VEGF-A and some non-mitogenic factors such as cytokines, CXC chemokines, and 
angiopoietins. Inhibitors of angiogenesis include the internal peptide fragments of 
extracellular matrix proteins (for instance, angiostatin and endostatin) [14, 17].  
The complex steps in new vessel formation have been intensively investigated in recent 
years. The main steps are: (1) tipping the angiogenic balance, (2) destabilization of pre-
existing blood vessels basement membrane by protease, (2) cell adhesion, (3) migration of 
EC toward the angiogenic stimulus, (4) proliferation, (5) formation of a capillary tubes, (6) 
loop formation by connection of individual sprouts, (7) vessel wall maturation (alignment of 
pericytes and smooth muscle), (7) formation of new basement membrane [14, 15, 18].  
The ability of tumors to stimulate neovascularization is determined by their “angiogenic 
switch,” of which the on/off is dictated by the inflammatory or hypoxic microenvironment 
inside tumor [15].  
4. Inflammatory cells and cytokines in tumor angiogenesis  
The above two processes, angiogenesis and inflammation, are closely linked in the following 
ways: (i) they are coupled in some chronic inflammatory diseases including Crohn disease, 
diabetes, psoriasis, rheumatoid arthritis, osteoarthritis, obesity, ocular diseases as well as 
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cancer; (ii) inflammatory cells interact with endothelial cells, fibroblasts and ECM in the 
inflamed loci; and (iii) the same molecular events trigger both inflammation and 
angiogenesis (Table 2) [19].  
 
Factors Biological activity 
VEGF 
Inducing confluent microvascular ECs to invade collagen gels and form 
capillary like structures, in vitro [81] 
Angiogenic properties in the chick chorioallantoic membrane, the rabbit 
cornea and numerous mice xenograft models, in vivo[21] 
Elevated VEGF levels and its correlation with increased risk of metastasis 
and overall poor prognosis in different cancers, reviewed by Ferrara [82] 
IL 
IL-1ǃ increasing EC outgrowth independently of VEGF, in vivo [83] 
IL-6 inducing vascular EC proliferation, tube formation and VEGF 
expression, in vitro [84] 
Eicosanoids 
12(S)-HETE and 15-HETEs as mediators of insulin and EGF-stimulated 
mammary epithelial cell proliferation and as synergistic effectors of bFGF- 
and PDGF-regulated growth of vascular endothelial cells, in vitro [15] 
LXs 
Synthetic analog of ATL inhibiting VEGF- and LTD4-stimulated 
angiogenesis, in vitro and in vivo [37, 85]; inhibiting actin cytoskeleton 
reorganization of EC stimulated with VEGF, in vitro [86] 
LXA4 inhibiting proinflammatory cytokine responses; attenuating LTD4 
and VEGF-stimulated proliferation and tube formation, in vitro [35] 
Chemokines 
CXCL8, induced by Ras to enhance VEGF-A and then acting on ECs to 
promote vessel formation, in vitro [39] 
CXCL12 promoting GSC-initiated angiogenesis by stimulating VEGF 
production, in vitro and in vivo [87] 
Table 2. Effect of variety of inflammatory mediators on angiogenesis. 
The role of inflammatory cells and cytokines in tumor angiogenesis is discussed in details in 
the following.  
4.1 VEGF and tumor angiogenesis 
VEGF-A, one of the most essential stimulators in tumor angiogenesis, was first reported by 
Senger, Dvorak and co-workers back in 1983 [20]. Collectively, the evidence from over 2 
decades of experimental work together with the recent clinical results firmly put VEGF as 
the central mediator in promoting angiogenesis via a direct effect on ECs and mainly 
through its binding to VEGFR-2 [21]. Another major effect of VEGF-A in the angiogenesis, 
cancer and metastases process is the ability to increase vascular permeability. It has been 
postulated that VEGF increases permeability by increasing the vesico-vascular organelles, 
fenestrations and trans-cellular gaps [22, 23]. In cancer, under the influence of VEGF, 
metastases to the peritoneal cavity leads to vascularization and hyper-permeability leads to 
malignant ascites formation and death.  
VEGF-A is up-regulated by transcription factor hypoxia inducible factor alpha (HIF1-) in 
response to various stimuli including hypoxia, cytokines, growth factors and nitric oxide. As 






and postnatal life in both physiological and pathophysiological processes such as tumor 
growth, ischemia and tissue repair. It could respond to reduced oxygen tensions and control 
the expression of many genes involved in metabolism, angiogenesis, tumorigenesis, and 
metastasis [24]. The activity and amount of HIF-1 are regulated through proteasomal 
degradation by hydroxylation of its proline residues. Under hypoxia, a condition commonly 
occurring in growing solid tumors, the enzymatic activity of hydroxylases is limited. As a 
result, HIF1-ǂ subunit is stabilized. This leads to formation of the dimer that enters the 
nucleus and binds to promoters of target genes, thereby inducing transcription of VEGF-A 
and other angiogenic factors [25]. 
4.2 Eicosanoids and tumor angiogenesis 
Metabolism of archidonic acid (AA) through cyclooxygenase (COX), lipoxygenase (LOX),  or 
P450 epoxygenase pathways leads to the formation of various eicosanoids that have potent 
biologic effects on a wide spectrum of physiological and pathological processes, including 
inflammation, fever, arthritis, and cancer. In the past decade, eicosanoids have emerged as key 
regulators of cancer progression. Studies using molecular and pharmacological approaches 
have found that enzymes involved in the eicosanoid production are overexpressed in cancer 
cells, enhance their angiogenic potential and simulate tumor growth in vivo [15]. 
Human prostate carcinoma (PCa) is a typical example to illustrate the influence of 
eicosanoids on tumor angiogenesis. It was indicated that the extent of angiogenesis is 
associated with PCa progression and the level of vascularization positively correlates with 
tumor stages [15]. There are several reports describing an increase in COX-2 expression in 
PCa tumors as compared with normal epithelial tissues [15]. Liu et al. examined the 
relationship between COX-2 expression and VEGF-A production under cobalt chloride 
(CoCl2)-stimulated hypoxia in three human PCa cell lines. This study performed in a human 
metastatic prostate cancer cell line determined that VEGF-A induction by CoCl2-induced 
hypoxia is maintained by a concomitant and persistent increase of COX-2 expression and 
sustained elevation of PGE2 synthesis. This finding suggested that COX-2 activity, reflected 
by PGE2 production, is involved in hypoxia-induced VEGF-A expression, which, in turn, 
modulates prostatic tumor angiogenesis [26]. They further tested the effect of COX-2 
inhibitor, NS398, in vivo. NS398 efficiently inhibited growth of tumors from PC-3 cells in 
mice by decreasing angiogenesis and VEGF-A expression [27].  
The pro-angiogenic effects of COX-2 are mediated primarily by three products of AA 
metabolism: thromboxane A2 (TXA2), prostaglandin E2 (PGE2), and prostaglandin I2 (PGI2). 
Downstream pro-angiogenic actions of these eicosanoid products include: (1) production of 
VEGF-A [28]; (2) promotion of vascular sprouting, migration, and tube formation [15]; (3) 
enhanced EC survival via Bcl-2 expression and Akt signaling [29]; (4) activation of 
epidermal growth factor receptor-mediated angiogenesis [30]. 
LOX is another lipid peroxidase dioxygenase family responsible for eicosanoids production. 
Overexpression of 12-LOX and 15-LOX in prostate cancer cells stimulates tumor 
angiogenesis and growth. For example, both EC migration and Matrigel implantation assays 
indicated that stable expression of 12-LOX in PC-3 cells increased their angiogenic potential 
compared with neomycin control [15]. These findings suggest that increased expression of 
12-LOX in human PCa cells stimulates growth of prostate tumors by enhancing their 
angiogenicity. Similar observations regarding the role of 12-LOX in tumor angiogenesis 
were also made in breast cancer [31]. The product of 12-LOX, 12(S)-HETE, has been found  
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to exert various effects on endothelial cells [15]. It was demonstrated that, when co-
incubated with microvascular ECs, Lewis lung carcinoma cells or B16 melanoma (B16a) cells 
can synthesize 12(S)-HETE in sufficient amounts to induce EC retraction [32]. The fact that 
tumor cell–induced EC retraction could not be blocked by COX inhibitors, but by a specific 
LOX inhibitor, BHPP, provided further proof that LOX enzyme plays an important role in 
tumor angiogenesis [32]. Some studies indicated that 12(S)-HETE act as a mitogen for 
microvascular ECs. The expression of 15-LOX-1 in PC-3 tumors cells was also found to 
stimulate tumor angiogenesis and growth [33]. Besides 12-LOX and 15-LOX, 5-LOX was also 
shown to promote tumor development by potentiating the pro-angiogenic response [34].  
More recent evidence has emerged the role of Lipoxins (LXs) and other lipid mediators, 
including the resolvins and neuroprotectins whose biosynthesis is linked in space and 
time to the resolution phase of an inflammatory response [35]. LXs have previously been 
shown to modulate responses of ECs including stimulation of prostacyclin production by 
human umbilical vein endothelial cell (HUVEC) [36]. Using HUVEC, Bake and his 
colleges demonstrated that LXA4 inhibited VEGF-A-stimulated inflammatory responses 
including IL-6, TNF-ǂ, IFN-ǃ and IL-8 secretion, as well as endothelial ICAM-1 
expression, and up-regulated an inflammatory inhibitor, IL-10. Consistent with these anti-
inflammatory and pro-resolution responses to LXA4, they found that LXA4 inhibited 
leukotriene D4 and VEGF-A-stimulated proliferation and angiogenesis, as determined by 
tube formation of HUVEC. It was believed that the underlying molecular mechanisms is 
associated with the decrease of VEGF-A-stimulated VEGF receptor-2 (VEGFR-2) 
phosphorylation and downstream signaling events including activation of phospholipase 
C-Ǆ, ERK1/2, and Akt [35]. Effects of LXA4 on ECs may be of particular relevance given 
the biosynthesis of this agent within the inflamed vasculature. In human enterocytes and 
leukocytes, LXA4 and its analogs inhibited the release of the cytokine IL-8 and IL-6, which 
has been recently reported to induce angiogenic activity in a carcinoma cell line. And, in 
an in vivo model, LXA4 and its synthetic analogs stimulated the production of IL-4, a 
cytokine with anti-angiogenic properties. Furthermore, the proteolytic activity necessary 
to digest the basement membrane, a crucial step in the angiogenic process, can be 
regulated by LXs at nanomolar concentration through preventing the synthesis of 
metalloproteinases (MMP) and increasing the tissue inhibitor of metalloproteinase (TIMP-
1) protein. Collectively, these data indicate that LXs regulate EC responses in vitro and in 
vivo which are relevant for tumor-angiogenesis [14].  
Aspirin-triggered-15-epi-lipoxins (ATL) is one analogue of LXA4. It is well known that 
aspirin’s therapeutic mechanism of its anti-inflammatory action is through acetylation of 
COX-2 and inhibition of COX-2-derived eicosanoids. Furthermore, acetylated COX-2 could 
also induce the biosynthesis of ATL in different types of cell, including ECs [34]. ATL are 
generated in vivo during cell–cell interactions, that can involve, for example, EC–
neutrophils, and display potent inhibitory actions in several key events in inflammation 
[14]. It is noteworthy that the modulation of EC proliferation and VEGF receptor signal 
transduction reported by Bake closely parallels the bioactions of the synthetic ATL which 
has been reported to inhibit VEGF-stimulated proliferation of HUVEC with a maximal effect 
of 50% at 10 nM , suggesting similar efficacy to LXA4 [37].  
4.3 Chemokines family and tumor angiogenesis 
Chemokines govern directed chemotaxis in nearby responsive cells during immune 
responses and inflammatory reactions by signaling through corresponding Gi protein-






(CCR) family. In recently years, chemokine family, including ligands and receptors, has 
become the focus in anti-tumor research field.  
CXCL8, one of glutamic acid-leucine-arginine (ELR+) chemokine, is up-regulated in several 
types of cancers, including pancreatic, lung, melanoma, breast, prostate and ovarian cancers 
[38]. In human cervical epithelioid carcinoma HeLa cell, CXCL8 was also induced by Ras, 
which has been shown to enhance VEGF-A and then act on endothelial cells to promote 
vessel formation [39]. Conversely, inhibition of CXCL8 led to an increase in tumor necrosis 
consistent with a defect in tumor vasculature and paracrine mechanism of action.  
Activation of CXCR by ELR+ CXC chemokines would elicit a localized immune response, 
which could facilitate angiogenesis [4]. CXCR2 is proved to be a common receptor shared by 
most ELR+ CXC chemokines. Activation of this receptor expressed in ECs had been shown 
to inhibit endothelial apoptosis, and induce migration and tube formation in ECs, processes 
linked to angiogenesis [40]. In a study on syngeneic murine Lewis lung cancer ectopic and 
orthotopic tumor model systems in CXCR2(+/+) and CXCR2(-/-) C57BL/6 mice, 
morphometric analysis of the primary tumors in CXCR2(-/-) mice demonstrated increased 
necrosis and reduced vascular density. These findings were further confirmed in 
CXCR2(+/+) mice using specific neutralizing antibody to CXCR2. The results of these 
studies support the notion that CXCR2 mediates the angiogenic activity of ELR(+) CXC 
chemokines in a preclinical model of lung cancer [41]. Similar effect of ELR(+) CXC 
chemokines and CXCR2 on tumor-associated angiogenesis was also shown in pancreatic 
cancer [42]. In vitro, ELR+ CXC chemokines in supernatants from multiple pancreatic cancer 
cell lines had significantly higher level compared with an immortalized human pancreatic 
ductal epithelial cell line. Furthermore, both recombinant ELR+ CXC chemokines and co-
culturing with BxPC-3 significantly enhanced proliferation, invasion, and tube formation of 
HUVEC. These biological effects were significantly inhibited by treatment with a 
neutralizing antibody against CXCR2. In vivo, anti-CXCR2 antibody significantly reduced 
tumor volume as well as proliferation index and Factor VIII microvessel density.  
CXCL12, ligand of CXCR4 receptor, also possesses angiogenic properties and is involved in 
the outgrowth and metastasis of CXCR4-expressing tumors and in certain inflammatory 
autoimmune disorders, such as rheumatoid arthritis [43].  
4.4 Inflammation-related miRNA and tumor angiogenesis 
In recent years, light has been shed on the connection between inflammation-related miRNA 
and tumor progression [9]. Two biologically active miRNAs, miR-126 and its complement 
miR-126*, have been reported to impair cancer progression through signaling pathways that 
control tumor cell proliferation, migration, invasion, and survival. Conversely, they may 
have a supportive role in the progression of cancer as well, which might be mediated by the 
promotion of blood vessel growth and inflammation. This effect of miR-126 and miR-126* 
on vascular functions could be explained by the fact that they are encoded by the intron 7 of 
the epidermal growth factor-like domain 7 (egfl7) gene. The endothelial cell-derived 
secreted protein EGFL7 has been suggested to control vascular tubulogenesis. Knock-out 
studies in zebrafish and mice suggested a major role of miR-126 in angiogenesis and 
vascular integrity, which was mediated by the repression of inhibitors of VEGF-A-induced 
proliferation in ECs.  
4.5 Inflammatory cells and tumor angiogenesis 
Tumor-associated macrophages (TAM) are prominent in the stromal compartment of 
virtually all types of malignancy. These highly versatile cells respond to the presence of  
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stimuli in different parts of tumors with the release of a distinct repertoire of growth factors, 
cytokines, chemokines, and enzymes [44]. Plasticity and diversity have long been known as 
hallmarks of the monocyte-macrophage differentiation pathway under inflammatory 
conditions [45]. Inflammation-induced angiogenesis is accompanied by macrophage 
infiltration. M2-type macrophages support angiogenesis and lymphangiogenesis by 
releasing pro-angiogenic growth factors such as IL-8, VEGF-A, VEGF-C and EGF [46, 47]. In 
a pancreatic cancer model, IL-4 induced high expression of cathepsin in TAM that then 
mediated tumor growth, angiogenesis and invasion in vivo [48]. TAM have also been 
demonstrated as the main cells producing semaphorin 4D within the tumor stroma. The 
latter is critical for tumor angiogenesis and vessel maturation [49]. There is a significant 
correlation between the number of infiltrating macrophages and the microvascular density 
or tumor tumor progression levels in glioblastomas and melanoma [50, 51].  
EC activation is manifested through chemokine production and up-regulation of surface 
adhesion molecules that facilitate adhesion of leukocytes that, in turn, cause more 
pronounced inflammation [52]., Leukocytes including TAM not only activate ECs but also 
promote and strengthen the entire process of tumor angiogenesis.  
5. Oxidative stress in tumor angiogenesis  
Dysregulation of redox status is a typical feature of many types of cancer [25]. It is widely 
accepted that the imbalance between the generation and clearance of reactive 
oxygen/nitrogen species (ROS/RNS) aids the development of the tumor mainly by 
inducing genomic instability. However, recent research has provided multiple evidences 
that ROS and other free radicals, such as nitric oxide, often produced at elevated levels 
within tumor tissue, may function as signaling molecules that initiate and/or modulate 
different regulatory pathways involved in tumorigenesis and metastasis [53]. High levels of 
ROS induce cell death, apoptosis and senescence; however, at the same time, low levels of 
ROS are important mediators in signaling pathways regulating growth and survival of 
endothelial and other cells [25, 54].  
The role of ROS in angiogenesis is well established. ROS were demonstrated to trigger the 
secretion of the most potent angiogenic factor – VEGF-A, in many cell types and induce 
proliferation, migration, cytoskeletal reorganization and tubular morphogenesis in ECs in 
vitro [55-57]. Increased intracellular levels of ROS were demonstrated in different settings to 
stabilize HIF1-, a key upstream regulatory of VEGF-A expression, not only under tumor 
hypoxia but also under normoxic conditions [58]. For example, up-regulation of HIF-1ǂ in 
response to stimulation with angiotensin II (Ang II) and thrombin was shown to be 
dependent on the elevation of H2O2 levels and cells with compromised antioxidant capacity 
in normoxia [59].  
6. Current treatments of inflammation-stimulated tumor angiogenesis  
Folkman's original hypothesis has opened a new era in today's biomedical research and 
changed the face of cancer medicine [60]. Modulation of angiogenesis for disease therapy 
was proposed nearly 40 years ago. As a result, many protein-based and chemical anti-
angiogenic drugs have been developed for treating human malignancies.  
In fact, since the VEGF-A discovery and characterization and subsequent determination of 






effort has been put into developing anti-VEGF agents.. In 2004, after 3-decades preclinical 
validation, bevacizumab, a humanized anti-VEGF-A neutralizing antibody, was approved 
by the US FDA for the clinical use to treat metastatic colorectal cancer in human patients 
[61]. This antibody was the first specific angiogenic inhibitor for use in clinical oncology. 
And following this initial success, bevacizumab has been expanded as one of the key 
component of the first-line therapeutic choices against various human cancers [60]. Clinical 
trials have reported positive response from patients treated with bevacizumab as a single 
agent or in combination with cytotoxic agents [62, 63].  
Beside bevacizumab, various other types of molecules have been developed to target the 
VEGF pathway. These include proteins that bind VEGF such as VEGF trap, VEGF receptor 
antibody IMC-1121B or antagonists such as vatalinib, inhibitors of receptor tyrosine kinase 
such as sunitinib, sorafenib, and ZD6474 [64, 65]. There are also vaccines based on 
xenogeneic or non-xenogeneic homologous molecules targeting VEGF-A or VEGFR [66].  
Unfortunately, patients with various types of tumors have different response to anti-
angiogenic therapy. While a small fraction of most common solid tumors such as colorectal, 
lung and breast cancers respond, some cancer types show intrinsic refractoriness [60]. But, 
we should not forget that the effectiveness of almost all therapeutic modalities is influenced 
by the micro-architecture and the gradients of essential nutrients around vessels [16]. This 
has been the driving force in the fields of anti-angiogenic drug development in tumor 
therapy.  
For prostate cancer, it has been shown that androgen regulates the expression of VEGF-A 
and that androgen withdrawal regresses prostate tumors, partly, by restraining their 
blood supply. Since prostate cancer eventually progresses to androgen independence, 
other mechanisms must take over at later stages of tumor [15]. In vivo, COX-2 inhibitor, 
NS398, efficiently inhibited growth of PC-3 tumors in mice and decreased angiogenesis. 
The same study showed that VEGF-A expression was also significantly down-regulated in 
the NS398-treated tumors [27]. Various well-documented clinical and experimental 
studies have also confirmed the effect of NSAIDs in the prevention of certain types [14]. 
The mechanism of aspirin acts to reduce the incidence and risk of these cancers is not 
clear but some articles indicated that it is result from the reduction of angiogenesis [67, 
68]. Epidemiologic studies show that individuals taking nonselective COX inhibitor or 
NSAIDs, including aspirin, have a significant reduction in CRC mortality, compared with 
those who did not these drugs [69].  
In vivo, anti-CXCR2 antibody significantly reduced tumor volume as well as proliferation 
index and Factor VIII microvessel density [42]. Thus, CXCR2 should be considered as a 
novel anti-angiogenic target in pancreatic cancer.  
ROS scavenging by antioxidants was recently demonstrated to inhibit angiogenesis in a 
model of myocardial infarction in rats [11]. Current clinical anti-angiogenic approaches in 
oncology exploit VEGF-A-VEGFR-2 axis, with the application of VEGF-A neutralizing 
antibodies (bevacizumab) and small-molecule VEGFR-2 tyrosine kinase inhibitors 
(sorafenib, sunitinib) [21]. However, this treatment do not provide a cure but only 
moderately prolongs patients’ lives [21, 70]. Recent progress in the understanding of redox 
modulation of regulation and signaling of VEGF-A may create possibilities to develop more 
universal anti-angiogenic drugs by targeting ROS.  
Intensive research resulted in the development of several FDA-approved drugs on 
angiogenesis in tumor. However, most of the clinical trials of single anti-angiogenic agents 
in combination with traditional anticancer treatment yielded disappointing results. Thus, 
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targeting multiple pathways regulating angiogenesis, such as inflammation, has been 
considered a promising target for therapeutic interventions. These clinically related issues 
need to be further addressed at molecular levels to understand the underlying mechanisms. 
Elucidation of molecular mechanisms linking cancer and inflammation may provide new 
targets for inhibition of angiogenesis and tumor progression.  
7. Abbreviation 
Arachidonic acid, AA; 
Aspirin-triggered-15-epi-lipoxins, ATL; 
Cancer-related inflammation, CRI;  
Cyclooxygenase, COX; 
CXC chemokine receptor, CXCR; 
CC chemokine receptor, CCR; 
Endothelial cell, EC; 
Fibroblast growth factor, FGF;  




Short noncoding RNAs termed microRNAs, miRNAs; 
Non-steroidal anti-inflammatory drugs, NSAIDs; 
Prostate carcinoma, PCa; 
Prostaglandin E2, PGE2; 
Prostaglandin I2, PGI2; 
Tumor-associated macrophages, TAM; 
Thromboxane A2, TXA2; 
Tissue inhibititor of metalloproteinase , TIMP-1; 
Transforming growth factor-α, TGF-α;  
Vascular endothelial growth factor-A, VEGF-A;  
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